Cost-effectiveness of the Recommendations of the Advisory Committee on Immunization Practices for the Recombinant Adjuvanted Zoster Subunit Vaccine.
other · Level V
Where this comes from
- Record sourced from PubMed, PMID 29987323.
- Also identified by DOI 10.1001/jamainternmed.2018.3200 and PMC identifier 6583213.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
This cost-effectiveness study evaluates use of the recombinant adjuvanted zoster subunit vaccine among patients 50 years and older.
Medical subject headings
- Advisory Committees
- Drug Costs
- Herpes Zoster
- Herpes Zoster Vaccine
- Immunization
- Practice Guidelines as Topic